The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- Podcast 162 – Assessing Fluid Responsiveness - November 29, 2015
- Podcast 161 – The New Fluid Assessment in Sepsis with Jean-Francois Lanctot - November 20, 2015
- Podcast 160 – Sepsis smaccDOWN - November 3, 2015